OASIS 1 trial: Oral semaglutide 50mg achieves 15.1% weight lossHeadline results from OASIS 1 - a phase 3a 68-week, efficacy and safety trial comparing once-daily oral semaglutide 50 mg for weight...
Standardisation of OAGB is key to reducing surgical errors and ensuring consistent patient outcomes2 days ago